Gap19 TFA|西域试剂

Gap19 TFA,99.93%

产品编号：Bellancom-P1136A| 分子式：C₅₇H₉₇F₃N₁₄O₁₅| 分子量：1275.46

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1136A	￥1500.00	杭州北京（现货）
Bellancom-P1136A	￥4500.00	杭州北京（现货）
Bellancom-P1136A	￥7500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Gap19 TFA

产品介绍

Gap19 TFA 是一种衍生自 Cx43 细胞质环 (CL) 九个氨基酸的肽，一种有效的，选择性连接蛋白 43 (Cx43) 半通道阻滞剂。Gap19 TFA 可以防止 C 末端 (CT) 与 CL 的分子内相互作用。Gap19 TFA 不阻断 GJ 通道或 Cx40/pannexin-1 半通道。Gap19 TFA 对心肌具有保护作用。

生物活性

Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial.

体外研究

Gap19 TFA (250 μM; for 30 min ) decreases mitochondrial potassium uptake.
Gap19 TFA (400 μM) inhibits unitary hemichannel currents in HeLa-Cx43 cells.
Gap19 TFA (100 μM) inhibits hemichannel unitary currents in ventricular cardiomyocytes.
Gap19 TFA (250 μM, 30 min) protects against myocardial ischemia/reperfusion injury in vitro and in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Gap19 TFA (iv; 25 mg/kg; 10 min before ligation) significantly reduces the infarct size by approximately one-fifth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57/BL6 mice
Dosage:	25 mg/kg
Administration:	IV; 10 min before ligation
Result:	Significantly reduced the infarct size by approximately one-fifth.

体内研究

Gap19 TFA (iv; 25 mg/kg; 10 min before ligation) significantly reduces the infarct size by approximately one-fifth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57/BL6 mice
Dosage:	25 mg/kg
Administration:	IV; 10 min before ligation
Result:	Significantly reduced the infarct size by approximately one-fifth.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (78.40 mM; Need ultrasonic)

H₂O : 100 mg/mL (78.40 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.7840 mL	3.9202 mL	7.8403 mL
5 mM	0.1568 mL	0.7840 mL	1.5681 mL
10 mM	0.0784 mL	0.3920 mL	0.7840 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶